RT Journal Article
SR Electronic
T1 In search for the SARS-CoV-2 protection correlate: A head-to-head comparison of two quantitative S1 assays in a group of pre-characterized oligo-/asymptomatic patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.19.21252080
DO 10.1101/2021.02.19.21252080
A1 Rubio-Acero, Raquel
A1 Castelletti, Noemi
A1 Fingerle, Volker
A1 Olbrich, Laura
A1 Bakuli, Abhishek
A1 Wölfel, Roman
A1 Girl, Philipp
A1 Müller, Katharina
A1 Jochum, Simon
A1 Strobl, Matthias
A1 Hoelscher, Michael
A1 Wieser, Andreas
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.19.21252080.abstract
AB Background Quantitative serological assays detecting response to SARS-CoV-2 infection are urgently needed to quantify immunity. This study analyzed the performance and correlation of two independent quantitative anti-S1 assays in oligo-/asymptomatic individuals from a previously characterized population-based cohort.Methods A total of 362 samples included 108 from individuals who had viral RNA detected in pharyngeal swabs, 111 negative controls and 143 samples with positive serology but not confirmed by RT-PCR. Blood plasma was tested with quantitative assays Euroimmun Anti-SARS-CoV-2 QuantiVac ELISA (IgG) (EI-S1-IgG-quant) and Roche Elecsys® Anti-SARS-CoV-2 CoV-2 S (Ro-RBD-Ig-quant), which were compared with each other and with confirmatory tests, including wild-type virus micro-neutralization (NT) and GenScript®cPass™. Results were analyzed using square roots R of coefficients of determination for association among continuous variables and non-parametric tests for paired comparisons.Results Quantitative anti-S1 serology correlated well with each other (96%/97% for true-positives and true-negatives, respectively). Antibody titers decreased over time (from <30 days to >240 days after initial positive RT-PCR). Agreement with GenScript-cPass was 96%/99% for true-positives and true-negatives, respectively, for Ro-RBD-Ig-quant and 93%/97% for EI-S1-IgG-quant. Ro-RBD-Ig-quant allowed a distinct separation between positive and negative values, and less non-specific reactivity compared with EI-S1-IgG-quant. Raw values (with 95% CI) ≥28.7 U/mL (22.6–36.4) for Ro-RBD-Ig-quant and ≥49.8 U/mL (43.4–57.1) for EI-S1-IgG-quant predicted virus neutralization >1:5 in 95% of cases.Conclusions Both quantitative anti-S1 assays, Ro-RBD-Ig-quant and EI-S1-IgG-quant, may replace direct neutralization assays in quantitative measurement of immune protection against SARS-CoV-2 in certain circumstances in the future.Key points Two quantitative anti-S1 assays showed similar performance and a high level of agreement with direct virus neutralization and surrogate neutralization tests, arguing for their utility in quantifying immune protection against SARS-CoV-2.Competing Interest StatementRRA, NC, AB, RW, PG and KM report no competing interests. LO reports non-financial support from Roche Diagnostics, Euroimmun, Viramed, Mikrogen, grants, non-financial support and other support from German Center for Infection Research (DZIF), grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial support from Munich Police, non-financial support and other support from Accenture. MH reports personal fees and non-financial support from Roche Diagnostics and DrBox, non-financial support from Euroimmun, Viramed and Mikrogen, grants, non-financial support and other support from German Center for Infection Research (DZIF), grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial support from Munich Police, non-financial support and other support from Accenture. SJ and MS are employees of Roche Diagnostics GmbH. AW reports personal fees and non-financial support from Roche Diagnostics and DrBox, non-financial support from Euroimmun, Viramed and Mikrogen, grants, non-financial support and other support from German Center for Infection Research (DZIF), grants and non-financial support from Government of Bavaria, non-financial support from BMW, non-financial support from Munich Police, non-financial support and other support from Accenture. MH and AW report a pending patent application on a sample system for sputum diagnostics of SARS-CoV-2. AW is involved in other different patents and companies not in relation with the serology of SARS-CoV-2. AW reports personal fees and other from Haeraeus Sensors, non-financial support from Bruker Daltonics, all of which are outside the submitted work, and non-related to SARS-CoV-2. Funding StatementThis work was supported by Bavarian State Ministry of Science and the Arts; University Hospital; Ludwig-Maximilians-Universitaet Munich; Helmholtz Centre Munich; University of Bonn; University of Bielefeld; German Ministry for Education and Research (proj. nr.: 01KI20271) and the Medical Biodefense Research Program of the Bundeswehr Medical Service. Euroimmun, Roche Diagnostics, Mikrogen, Viramed provided kits and machines for analyses at discounted rates. Editorial support was provided by Olga Ucar of inScience Communications, Springer Healthcare Ltd, UK, and was funded by Roche Diagnostics.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:LMU ethics committee ruling number: 20-275 Board Chairman: Prof. Dr. Wolfgang Eisenmenger, Rechtsmediziner (Head of commission) Deputy Chairman: Prof. Dr. Rudolf M. Huber (Internist/Pneumologe) / Prof. Dr. Clemens Wendtner (Internist/Onkologe) Members: Prof. Dr. Heinz Angstwurm (Neurologe) Dr. Gina Atzeni (Soziologin) Prof. Dr. Stefan Boeck (Internist/Onkologe) Hans-Joachim Eckert (Jurist mit Befaehigung zum Richteramt) Prof. Dr. Bertold Emmerich (Internist/Onkologe) Prof. Dr. Stefan Endres (Internist/Klinischer Pharmakologe) Prof. Dr. Rainald Fischer (Internist/Pneumologe) Prof. Dr. Roland Gaertner (Endokrinologe, Intensivmediziner) Prof. Dr. Orsolya Genzel-Boroviczeny (Paediaterin) Prof. Dr. Klaus Hahn (Radiologe/Nuklearmediziner) Prof. Dr. Nadia Harbeck (Gynaekologin) Dr. Beate Henrikus (Klinische Pharmakologin/Medizinethikerin) Prof. Dr. Christian Heumann (Biostatistiker) Prod. Dr. Reinhard Hohlfeld (Neuroimmunologe) Prof. Dr. Axel Holstege (Internist/Gastroenterologe) Prof. Dr. Volker Klauss (Internist/Kardiologe) Dr. Florian Kohlmayer (Medizininformatiker) Dr. Katja Kuehlmeyer (Psychologin) Prof. Dr. Josef Franz Lindner (Jurist mit Befaehigung zum Richteramt) Prof. Dr. Stefan Lorenzl (Neurologe) Prof. Dr. Ulrich Mansmann (Biometriker, Epidemiologe) Prof. Dr. Georg Marckmann (Medizinethiker/Philosoph) Dr. Viktoria Moench (Apothekerin) Prof. Dr. Harald Mudra (Kardiologe) Prof. Dr. Klaus Juergen Pfeifer (Radiologe) Prof. Dr. Randolph Penning (Rechtsmediziner) Prof. Dr. Jochen Peters (Paediater) Dr. Rudolf Ratzel (Jurist) Prof. Dr. Hans Martin Schardey (Chirurg) Prof. Dr. Max Schmauss (Psychiater) Prof. Dr. Ulrich Schroth (Jurist mit Befaehigung zum Richteramt) Prof. Dr. Ortrud Steinlein (med. Genetikerin) PD Dr. Georg Stueben (Strahlentherapeut) Dr. Bettina Vogl (Biologin) Prof. Dr. Helmut Waldner (Chirurg) PD Dr. Ursula Wandl (Internistin/Onkologin/Versicherungsmedizinerin) Prof. Dr. Markus Woernle (Internist/Nephrologe/Intensivmediziner) Dr. rer. nat. Alexander Yassouridis (Mathematiker/Statistiker/Biometriker) Dr. Christian Zach (Diplom-Physiker) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are subject to data protection regulations and can be made available upon reasonable request to the corresponding author. To facilitate reproducibility and reuse, the code used to perform the analyses and generate the figures was made available on GitHub (https://github.com/koco19/lab_epi) and has been uploaded to ZENODO (http://doi.org/10.5281/zenodo.4300922, DOI 10.5281/zenodo.4300922) for long-term storage.